search
Back to results

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Primary Purpose

Familial Hypercholesterolemia

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Implitapide
Sponsored by
Medical Research Laboratories International
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Familial Hypercholesterolemia focused on measuring Heterozygous Familial Hypercholesterolemia (HeFH)

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: In order to participate in this study, patients must meet all of the following inclusion criteria: be between 18 and 70 years old with a diagnosis of HeFH; be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments; have an appropriate calculated, fasting LDL-C levels and an appropriate triglyceride (TG) level; be male or nonpregnant, nonlactating female; give informed consent; and meet body weight requirements. Exclusion Criteria: In order to participate in this study, patients must not meet any of the following exclusion criteria: recent myocardial infarction, percutaneous transluminal coronary intervention, coronary artery bypass graft surgery, or cerebrovascular accident; uncontrolled hypothyroidism or other uncontrolled endocrine disease; known, clinically significant eye abnormalities (e.g., cataracts); appropriate serum creatinine phosphokinase levels; history of liver disease or liver enzyme levels above appropriate levels; alkaline phosphatase above appropriate levels; serum creatinine above appropriate levels; liver cirrhosis and severe liver steatosis; clinically significant infection, malignancy, or psychosis; use of oral anticoagulants or digoxin, unless the dose has been stable for 4 weeks; participation in any other investigational study, including device or observational studies, within 30 days; lactating or have a positive serum pregnancy test; current drug or alcohol abuse; or unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the investigator

Sites / Locations

  • Metabolic and Atherosclerosis Research Center
  • Andromed Leiden
  • Andromed Rotterdam
  • Andromed Oost
  • Andromed Zoetermeer
  • Lipidklinikken - Rikshospitalet

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
March 17, 2004
Last Updated
June 23, 2005
Sponsor
Medical Research Laboratories International
search

1. Study Identification

Unique Protocol Identification Number
NCT00079859
Brief Title
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
Official Title
Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2005
Overall Recruitment Status
Terminated
Study Start Date
October 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Medical Research Laboratories International

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Familial Hypercholesterolemia
Keywords
Heterozygous Familial Hypercholesterolemia (HeFH)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
120 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Implitapide

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: In order to participate in this study, patients must meet all of the following inclusion criteria: be between 18 and 70 years old with a diagnosis of HeFH; be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments; have an appropriate calculated, fasting LDL-C levels and an appropriate triglyceride (TG) level; be male or nonpregnant, nonlactating female; give informed consent; and meet body weight requirements. Exclusion Criteria: In order to participate in this study, patients must not meet any of the following exclusion criteria: recent myocardial infarction, percutaneous transluminal coronary intervention, coronary artery bypass graft surgery, or cerebrovascular accident; uncontrolled hypothyroidism or other uncontrolled endocrine disease; known, clinically significant eye abnormalities (e.g., cataracts); appropriate serum creatinine phosphokinase levels; history of liver disease or liver enzyme levels above appropriate levels; alkaline phosphatase above appropriate levels; serum creatinine above appropriate levels; liver cirrhosis and severe liver steatosis; clinically significant infection, malignancy, or psychosis; use of oral anticoagulants or digoxin, unless the dose has been stable for 4 weeks; participation in any other investigational study, including device or observational studies, within 30 days; lactating or have a positive serum pregnancy test; current drug or alcohol abuse; or unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the investigator
Facility Information:
Facility Name
Metabolic and Atherosclerosis Research Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Name
Andromed Leiden
City
Leiden
Country
Netherlands
Facility Name
Andromed Rotterdam
City
Rotterdam
Country
Netherlands
Facility Name
Andromed Oost
City
Velp
Country
Netherlands
Facility Name
Andromed Zoetermeer
City
Zoetermeer
Country
Netherlands
Facility Name
Lipidklinikken - Rikshospitalet
City
Oslo
Country
Norway

12. IPD Sharing Statement

Learn more about this trial

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

We'll reach out to this number within 24 hrs